Researchers at USC have discovered that activating the Piezo1 protein reduces inflammation caused by immune cells in the lungs in response to allergens. ILC2s, a type of immune cell, play a crucial role in allergic asthma by driving inflammation in the lungs, leading to airway tightening. Activation of Piezo1 channels by a drug called Yoda1 reduces ILC2 activity, inflammation, and asthma symptoms in mice. Human ILC2s also produce Piezo1, indicating the potential for Yoda1 as a therapeutic tool for allergic asthma. Future studies will focus on developing Piezo1-driven therapeutics for treating asthma in humans.
Source link
Researchers identify new way to inhibit immune cells that drive allergic asthma
